COVID-19 Vaccines Clinical Trial
— AIMED COVIDOfficial title:
Understanding and Addressing the Disparity in Vaccination Coverage Among U.S. Adolescents Living in Rural Versus Urban Areas
Verified date | October 2022 |
Source | Marshfield Clinic Research Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A single COVID-19 booster dose has been recommended in the United States for adolescents aged ≥12 years to enhance protection against SARS-CoV-2 infection. This study will assess the efficacy of a one-time reminder/recall for COVID-19 booster dose among eligible adolescents in a regional healthcare system.
Status | Active, not recruiting |
Enrollment | 4304 |
Est. completion date | December 31, 2022 |
Est. primary completion date | August 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 17 Years |
Eligibility | Inclusion Criteria: - Marshfield Clinic Health System patient aged 12-17 years with at least one preventive visit or two evaluation & management visits with a Marshfield Clinic Health System provider in the last 36 months - Due for a COVID-19 booster dose (completed the COVID-19 primary series and it has been =5 months since their second dose) Exclusion Criteria: - Primary care provider is not affiliated with Marshfield Clinic Health System - Opted out of Marshfield Clinic Health System centralized vaccine reminder notifications - Received COVID-19 vaccine off label - Missing or invalid contact information - Deceased |
Country | Name | City | State |
---|---|---|---|
United States | Marshfield Clinic Health System | Marshfield | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Marshfield Clinic Research Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | COVID-19 Booster Dose | Number of patients that received a COVID-19 booster dose during follow-up based on electronic health data. Receipt of a COVID-19 booster dose within 90 days of randomization (yes/no) will be assessed using vaccination data available from the Marshfield Clinic Health System (MCHS) electronic health record, which includes vaccinations administered outside of MCHS through data exchanges with the Wisconsin Immunization Registry. Specifically patients will be classified as having received a COVID-19 booster dose if they have record of receipt of COVID-19 booster dose with a vaccination date during the 90-day follow-up period. | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05918939 -
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
|
Early Phase 1 | |
Active, not recruiting |
NCT06272253 -
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
|
Early Phase 1 | |
Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
Recruiting |
NCT05185817 -
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients
|
Phase 2 | |
Not yet recruiting |
NCT04876885 -
The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations
|
N/A | |
Completed |
NCT05373459 -
Effect of a Third COVID-19 Booster Among Health Care Workers
|
||
Completed |
NCT04888793 -
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
|
||
Completed |
NCT04881396 -
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
|
||
Recruiting |
NCT04871165 -
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
|
||
Active, not recruiting |
NCT05293665 -
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
|
Phase 3 | |
Active, not recruiting |
NCT05405283 -
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
|
Phase 3 | |
Recruiting |
NCT05508477 -
UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)
|
Phase 3 | |
Recruiting |
NCT05471635 -
Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
|
||
Recruiting |
NCT06282692 -
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
|
Phase 3 | |
Completed |
NCT05406908 -
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
|
Phase 4 | |
Recruiting |
NCT04895007 -
Comparative Evaluation of Covid-19 Vaccines Response
|
||
Recruiting |
NCT05831826 -
Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
|
||
Recruiting |
NCT05096260 -
Getting to Yes, Michigan! (G2YMI)
|
N/A | |
Completed |
NCT04962906 -
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
|
Phase 2 | |
Active, not recruiting |
NCT05027672 -
Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.
|
Phase 2 |